Vizsgálati helyszín
Lynn Health Science Institute
Oklahoma City, Oklahoma 73112, Egyesült ÁllamokMég nincs intézményhez kötve
- 14futó vizsgálat
- 18lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 32 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis20 vizsgálat
- 2. fázis5 vizsgálat
- 1. fázis3 vizsgálat
- 1/2. fázis2 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Lezárult14 vizsgálat
- Fut, nem toboroz10 vizsgálat
- Toboroz4 vizsgálat
- Leállították4 vizsgálat
- Fő szponzor
- Amgen4 vizsgálat
- Eli Lilly and Company4 vizsgálat
- ModernaTX, Inc.4 vizsgálat
- Pfizer4 vizsgálat
- Biogen2 vizsgálat
- és még 12
Futó vizsgálatok
Toboroz
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
NCT07837973· 2. fázis· Alveus Therapeutics, Inc.· Forrás
Contact: Lacey Dietz
Fut, nem toboroz
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
NCT07477704· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399· 3. fázis· Amgen· Forrás
Toboroz
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled Gout
NCT07388498· 3. fázis· Amgen· Forrás
Fut, nem toboroz
Study of GS-0151 in Participants With Rheumatoid Arthritis
NCT06902519· 1. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
NCT06565611· 2. fázis· Palatin Technologies, Inc· Forrás
Fut, nem toboroz
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
NCT05774756· 3. fázis· Rhythm Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
NCT05164094· 1/2. fázis· ModernaTX, Inc.· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· 3. fázis· Eisai Inc.· Forrás
Fut, nem toboroz
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
NCT02951598· Eli Lilly and Company· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
NCT06046443· 2. fázis· Rhythm Pharmaceuticals, Inc.· Forrás
Lezárult
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
NCT06229145· 4. fázis· Amgen· Forrás
Lezárult
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
NCT06178991· 3. fázis· BioNTech SE· Forrás
Lezárult
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864· 3. fázis· Boehringer Ingelheim· Forrás
Lezárult
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
NCT05975099· 1/2. fázis· ModernaTX, Inc.· Forrás
Lezárult
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05704738· 3. fázis· Amgen· Forrás
Lezárult
A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
NCT05696847· 1. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
NCT05596734· 2. fázis· BioNTech SE· Forrás
Lezárult
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
NCT05566639· 3. fázis· ModernaTX, Inc.· Forrás
Lezárult
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
NCT05540522· 3. fázis· Pfizer· Forrás
Lezárult
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
NCT05456529· 3. fázis· Incyte Corporation· Forrás
Leállították
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
NCT05310071· 3. fázis· Biogen· Forrás
Lezárult
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
NCT05169580· 1. fázis· Fulcrum Therapeutics· Forrás
Leállították
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
NCT05085366· 3. fázis· ModernaTX, Inc.· Forrás
Lezárult
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
NCT04392154· 3. fázis· Eli Lilly and Company· Forrás
Leállították
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
NCT04241068· 3. fázis· Biogen· Forrás
Leállították
Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031
NCT03573882· 3. fázis· Pfizer· Forrás
Lezárult
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822· 3. fázis· Pfizer· Forrás
Hibát jelzek